TWI224969B - Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease - Google Patents

Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease Download PDF

Info

Publication number
TWI224969B
TWI224969B TW088105322A TW88105322A TWI224969B TW I224969 B TWI224969 B TW I224969B TW 088105322 A TW088105322 A TW 088105322A TW 88105322 A TW88105322 A TW 88105322A TW I224969 B TWI224969 B TW I224969B
Authority
TW
Taiwan
Prior art keywords
cells
antibody
lupus
cell
pharmaceutical composition
Prior art date
Application number
TW088105322A
Other languages
English (en)
Chinese (zh)
Inventor
Randolph J Noelle
Christopher M Burns
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Application granted granted Critical
Publication of TWI224969B publication Critical patent/TWI224969B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW088105322A 1998-04-03 1999-06-28 Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease TWI224969B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03

Publications (1)

Publication Number Publication Date
TWI224969B true TWI224969B (en) 2004-12-11

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088105322A TWI224969B (en) 1998-04-03 1999-06-28 Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease

Country Status (9)

Country Link
EP (1) EP1067954A4 (OSRAM)
JP (1) JP2002510643A (OSRAM)
KR (1) KR20010072564A (OSRAM)
CN (2) CN100352497C (OSRAM)
AU (1) AU743824B2 (OSRAM)
HU (1) HUP0101689A3 (OSRAM)
NO (1) NO20004966L (OSRAM)
TW (1) TWI224969B (OSRAM)
WO (1) WO1999051258A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
NZ337072A (en) * 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
CN1173735C (zh) 2004-11-03
HUP0101689A3 (en) 2004-08-30
NO20004966L (no) 2000-12-04
AU3379699A (en) 1999-10-25
EP1067954A1 (en) 2001-01-17
EP1067954A4 (en) 2004-08-18
CN100352497C (zh) 2007-12-05
NO20004966D0 (no) 2000-10-02
JP2002510643A (ja) 2002-04-09
CN1757413A (zh) 2006-04-12
KR20010072564A (ko) 2001-07-31
HUP0101689A2 (hu) 2001-08-28
WO1999051258A1 (en) 1999-10-14
AU743824B2 (en) 2002-02-07
CN1303301A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
JP3447733B2 (ja) Ｔリンパ球表面のヒト糖蛋白質を認識するネズミモノクローナル抗体（５ｃ８）
JP4148537B2 (ja) Ｃｄ４０ｃｒレセプター及びそれに対するリガンド
CN109793893B (zh) 用于诊断和治疗癌症的vista调节剂
JP6665139B2 (ja) 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
EP0751781B1 (en) Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders
TWI222453B (en) Ligand for herpes simplex virus entry mediator and methods of use
US11285149B2 (en) Enhanced immunotherapy of cancer using targeted transcriptional modulators
JP6317674B2 (ja) 医学的使用のための二重特異性抗体
JP2002509431A (ja) ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
NZ543654A (en) GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
KR100850731B1 (ko) Ｐ-셀렉틴 당단백질 리간드 1의 조절자
BR112012024565B1 (pt) Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
Biancone et al. Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis
US20060110392A1 (en) Murine monoclonal antibody (5c8) recognizes T-B cell activating molecule (T-BAM) (CD40 LIGAND) on the surface of T-lymphocytes, compositions containing same and methods of use
Kerekov et al. Elimination of autoreactive B cells in humanized SCID mouse model of SLE
AU743824B2 (en) Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
US20020058037A1 (en) Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease
WO2025191260A1 (en) Treatment of autoimmune disease by co-expression of cd19-car and bcma-car
HK40057006B (zh) 嵌合受体及其方法和用途
Chen The role of Ox40-ligand in costimulation
HK1067887A (en) Antibodies that bind the cd40cr receptor

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees